ArticleBMJ open respiratory research2026
Integrated molecular networks reveal latent components distinguishing type 2-high and type 2-low asthma.
Article in BMJ open respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundType 2 inflammation (T2) biomarkers are used to identify T2-low and T2-high endotypes of asthma in the clinic and understanding of these endotypes has helped to improve clinical management of patients. The T2-low asthma endotype remains relatively poorly characterised and these patients have few treatment options. Despite its clinical relevance, this endotype lacks specific biomarkers.
objectiveTo identify transcriptional and microRNA signatures associated with asthma endotypes.
methodsWe studied 88 participants with asthma stratified into T2-high and T2-low asthma by blood eosinophils and/or fractional exhaled nitric oxide. We defined whole-blood microRNA and mRNA profiles for each participant and used Data Integration Analysis for Biomarker discovery using Latent Variable approaches for Omics integration to identify latent components (LCs). The results were validated in two independent cohorts of subjects with asthma, including patient samples taken before and after treatment with benralizumab.
resultsThe T2-high endotype was the most prevalent (67%, n=55) within the study population. We identified two LCs associated with T2-high and T2-low asthma. LC1 was characterised by eosinophil-derived mRNAs and included multiple T2-low microRNAs. LC2 was associated with both endotypes and non-eosinophilic cell types. Pathway analysis revealed increased representation of taste and smooth muscle pathways in the T2-low endotype. The T2-low microRNA miR-574-3p was enriched in LC1. Furthermore, we found that the LC signatures were present in two independent cohorts and modulated by benralizumab.
conclusionsT2-high and T2-low asthma are distinguished by unique transcriptomic networks and have minimal microRNA overlaps. T2-low asthma was enriched for pathways involved with smooth muscle contraction. The LCs signatures are also modulated by benralizumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.